BioSpace News Archive

The Family Heart Foundation, a leading research and advocacy organization, today announced study results that demonstrate individuals with elevated lipoprotein(a) – also referred to as Lp(a) —levels experience an increased rate of cardiovascular events.

Seagen Announces Positive Topline Results of Pivotal Phase 2 Clinical Trial of TUKYSA ® (tucatinib) in Combination With Trastuzumab in HER2-Positive Metastatic Colorectal Cancer.

Thermo Fisher Scientific, the world leader in serving science, and Qatar Genome Program (QGP), a member of Qatar Foundation (QF), have partnered with the goal of accelerating genomic research and clinical applications of predictive genomics in Qatar as a as a step toward expanding the benefits of precision medicine across Arab populations globally.

Biotricity Inc. is scheduled to present and will be participating in a fireside chat at the H.C. Wainwright Global Investment Conference, being held from May 23-26, 2022.

Edwards Lifesciences Corporation (NYSE: EW) today announced it is scheduled to present at the Bernstein 38th Annual Strategic Decisions Conference on Thursday, June 2 , 2022.

Daiichi Sankyo (TSE: 4568) will present new clinical research across its oncology portfolio at the 2022 American Society of Clinical Oncology Scientific Program (#ASCO22) and the European Hematology Association Congress (#EHA22).

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today it will present new data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting from June 3-7 in Chicago.

Immunome, Inc. today announced updates to the ongoing development of its lead oncology program, IMM-ONC-01, a novel immuno-oncology agent that inhibits IL-38, an immunosuppressive cytokine.

Revance Therapeutics, Inc., a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, announced that the company will participate in the William Blair 42nd Annual Growth Stock Conference, taking place June 6-9, in Chicago.

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that Juli Blanche has been appointed Chief People Officer and a member of the senior leadership team at Precision BioSciences.